This course is part of the Integrative Healthcare Symposium curriculum.
Webcast
1.00 CME/CE Credit
Current & Emerging Advanced Therapeutics in the IBD Landscape
Whereas steroids & surgery were the main avenues of therapy for Crohn’s & Ulcerative colitis patients in the past, novel research breakthroughs have permitted a new era of advanced immunotherapies, both biologics and small molecules, to emerge that are transforming patient care and outcomes in Inflammatory Bowel Disease (IBD). Learn the latest insights into how these new agents mechanistically accomplish and target gut disease. Emerging innovations in hyperbaric oxygen therapy and mesenchymal stem cell therapy will be reviewed.
CME/CE Information
1.00 AMA PRA Category 1 Credits™
Release Date: 3/8/2024
Expiration Date: 3/8/2025
Topics
Faculty
Learning Objectives
- Examine the epidemiology of Inflammatory Bowel Disease (IBD).
- Point out key differences in the clinical presentation of the two major IBD phenotypes: Crohn’s disease and Ulcerative colitis.
- Identify the basic mechanisms of action of different biologic and small molecule therapies in treating IBD.
- Investigate new research into the role of hyperbaric oxygen, mesenchymal stem cell therapy and microbiota restorative therapy for different forms of IBD.
Faculty
Neilanjan Nandi, MD, FACP
Associate Professor of Clinical Medicine, Inflammatory Bowel Diseases Center, Penn Presbyterian Medical Center, University of Pennsylvania, Philadelphia, PA
Learn MoreDisclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Neilanjan Nandi, MD, FACP: Consultant for Pfizer, Janssen, BMS AbbVie, and Boehringer Ingelheim
Non-faculty contributors and others involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Diversified Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Obtaining Credit
For APRNs and PAs, AANPCB and NCCPA accept AMA PRA Category 1 Credit™ as the number of hours of participation (AANPCB) or as Category 1 CME credits (NCCPA).
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.